HC Wainwright Comments on Geron’s Q1 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Geron in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS and Q3 2025 earnings at ($0.02) EPS.

Other analysts also recently issued reports about the company. Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target for the company. StockNews.com raised shares of Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partners initiated coverage on shares of Geron in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Geron in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.05.

Geron Price Performance

Shares of Geron stock opened at $3.97 on Monday. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -12.41 and a beta of 0.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. The stock has a 50 day moving average price of $4.29 and a 200-day moving average price of $4.32. Geron has a one year low of $1.64 and a one year high of $5.34.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.10% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same quarter last year, the business posted ($0.08) earnings per share. The firm’s revenue was up 17138.4% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Geron by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 29,869,287 shares of the biopharmaceutical company’s stock worth $98,569,000 after buying an additional 1,304,713 shares during the period. Darwin Global Management Ltd. purchased a new stake in Geron in the second quarter worth about $106,185,000. Farallon Capital Management LLC grew its holdings in Geron by 124.6% during the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after acquiring an additional 9,342,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Geron by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,450,382 shares of the biopharmaceutical company’s stock valued at $20,205,000 after purchasing an additional 111,361 shares during the period. Finally, First Turn Management LLC bought a new stake in shares of Geron in the 3rd quarter valued at about $14,187,000. Institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.